发明名称 ALTERNARIA PEPTIDES.
摘要 <p>Pharmaceutical formulations,which may be used for preventing or treating allergy to moulds of the Alternaria and/or Cladosporiumgenus, comprising a pharmaceutically acceptable carrier or diluent and a polypeptide or a pharmaceutically acceptable salt thereof selected from at least three of: (a)a polypeptide comprising the amino acid sequence of WSWKIGPAIATGNT(Alt28; SEQ ID NO: 101) or a T cell epitope-containing variant sequence derived from said amino acid sequence, or a said salt thereof; (b)a polypeptide comprising the amino acid sequence of KYRRVVRAGVKVAQTAR(Alt34A; SEQ ID NO: 107) or a T cell epitope-containing variant sequence derived from said amino acid sequence, or a said salt thereof; (c) a polypeptide comprising the amino acid sequence of KYAGVFVSTGTLGGG (SEQ ID NO: 112) or a T cell epitope-containing variant sequence derived from said amino acid sequence, or a said salt thereof; (d)a polypeptide comprising the amino acid sequence of AEVYQKLKALAKKTYGQ(Alt13A; SEQ ID NO: 83) or a T cell epitope-containing variant sequence derived from said amino acid sequence, or a said salt thereof; (e)a polypeptide comprising the amino acid sequence of SLGFNIKATNGGTLD(Alt01A; SEQ ID NO: 60)or a T cell epitope-containing variant sequence derived from said amino acid sequence, or a said salt thereof; (f) a polypeptide comprising the amino acid sequence of SAKRMKVAFKLDIEK(Alt06; SEQ ID NO: 72) or a T cell epitope-containing variant sequence derived from said amino acid sequence, or a said salt thereof; (g)a polypeptide comprising the amino acid sequence of DITYVATATLPNYCR(SEQ ID NO: 111) or a T cell epitope-containing variant sequence derived from said amino acid sequence, or a said salt thereof; and (h)a polypeptide comprising the amino acid sequence of GWGVMVSHRSGET(Alt14;SEQ ID NO: 84) or a T cell epitope-containing variant sequence derived from said amino acid sequence, or a said salt thereof; wherein a T cell epitope-containing variant sequence of a said amino acid sequence is said amino acid sequence having up to seven amino acid modifications, each of which is independently a deletion, substitution or insertion, and each polypeptide is up to 30 amino acids in length.</p>
申请公布号 MX2014014461(A) 申请公布日期 2015.02.10
申请号 MX20140014461 申请日期 2013.05.30
申请人 CIRCASSIA LIMITED 发明人 PAUL LAIDLER;RODERICK PETER HAFNER;PASCAL HICKEY;MARK LARCHE
分类号 C07K14/37;A61K39/35;A61P37/08 主分类号 C07K14/37
代理机构 代理人
主权项
地址